Effects of public trust on behavioural intentions in the pharmaceutical sector: data from six European countries

被引:7
|
作者
Balog-Way, Dominic [1 ]
Evensen, Darrick [2 ]
Lofstedt, Ragnar [3 ]
Bouder, Frederic [4 ]
机构
[1] Cornell Univ, Dept Commun, Ithaca, NY 14850 USA
[2] Univ Edinburgh, Polit & Int Relat Dept, Edinburgh, Midlothian, Scotland
[3] Kings Coll London, Kings Ctr Risk Management, Dept Geog, London, England
[4] Univ Stavanger, Ctr Risk Management & Societal Safety SEROS, Dept Safety Econ & Planning, Stavanger, Norway
关键词
Trust; risk perception; medicines; behaviour; European medicines agency; HEALTH INFORMATION-SEEKING; GENETICALLY-MODIFIED FOODS; MEDICINES AGENCY; MENTAL-HEALTH; TRIAL DATA; TRANSPARENCY; RISK; INTERNET; PERCEPTIONS; IMPACT;
D O I
10.1080/13669877.2019.1694962
中图分类号
C [社会科学总论];
学科分类号
03 ; 0303 ;
摘要
Few studies have empirically examined the relationship between trust and its consequences in the pharmaceutical context (e.g. the consequences of trust in medicines advice for patient behaviour). This study empirically examined the European public's perceived trustworthiness of medical, societal, and industry sources of medicines advice, and its consequences for their behavioural intentions including their medicine-taking and information-seeking behaviour. A representative survey (N = 6,001) was conducted with adults from six European countries: Great Britain, France, Germany, Denmark, Italy, and Poland. As expected, respondents consistently rated advice from medical sources (GPs, pharmacists, local hospitals, emergency services) as significantly more trustworthy than advice from societal sources (the Internet, friends/relatives, and the mass media) and, especially, industry (pharmaceutical companies and brand specific websites). A structural equation model then revealed strong associations between the public's perceived trustworthiness of these medical, societal, and industry sources and their medicine-taking and information seeking intentions. Important national variations were found including in the public's opinions on when authorities should convey new safety information. Implications for communicating benefit-risk information in a more transparent regulatory environment are discussed, including the importance of maintaining and strengthening trust in medical actors and committing more resources to supporting national risk communication.
引用
收藏
页码:645 / 672
页数:28
相关论文
共 50 条
  • [1] Transparency and trust in the European pharmaceutical sector: a Commentary
    Lofstedt, Ragnar
    Way, Dominic
    JOURNAL OF RISK RESEARCH, 2016, 19 (09) : 1120 - 1128
  • [2] Commentary on "Transparency and Trust in the European Pharmaceutical Sector'
    Breckenridge, Alasdair
    JOURNAL OF RISK RESEARCH, 2016, 19 (09) : 1118 - 1119
  • [3] Observations on "Transparency and trust in the European pharmaceutical sector'
    Miller, Andrew
    JOURNAL OF RISK RESEARCH, 2016, 19 (09) : 1111 - 1113
  • [4] Centralised Pharmaceutical Procurement: Learnings from Six European Countries
    Vogler, Sabine
    Bauer, Eveli
    Habimana, Katharina
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (05) : 637 - 650
  • [5] Centralised Pharmaceutical Procurement: Learnings from Six European Countries
    Sabine Vogler
    Eveli Bauer
    Katharina Habimana
    Applied Health Economics and Health Policy, 2022, 20 : 637 - 650
  • [7] Transparency and trust in the European pharmaceutical sector: outcomes from an experimental study
    Loefstedt, Ragnar
    Way, Dominic
    JOURNAL OF RISK RESEARCH, 2016, 19 (09) : 1082 - 1103
  • [8] Comment on paper "Transparency and trust in the European pharmaceutical sector'
    Meijer, Albert
    JOURNAL OF RISK RESEARCH, 2016, 19 (09) : 1104 - 1106
  • [9] THE EFFICIENCY OF THE PUBLIC SECTOR IN EUROPEAN COUNTRIES
    Hamernikova, Bojka
    Kubat, Jan
    PROCEEDINGS OF THE 9TH INTERNATIONAL CONFERENCE EUROPEAN ENTREPRENEURSHIP FORUM 2015: EFFICIENCY IN THE PRIVATE AND THE PUBLIC SECTOR, 2016, : 57 - 65
  • [10] Trust in sources of diabetes information in six European countries
    Lin, E.
    Cox, E.
    Bell, T.
    Bristow, T.
    Wood, R.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S444 - S444